MRS efficacy in distinction between benign and malignant lesions

  Considering non-invasive, sensitivity and appropriateness of Magnetic Resonance Spectroscopy and its ability to detect prostate lesions in the early stages; this study aimed to review the MRS efficacy to distinguish benign and malignant prostate lesions, systematically. PubMed, Science Direct, Embase, Cochran and Scopus databases were explored using the MRS & prostate, prostate, prostatitis, BPH, and Magnetic Resonance Spectroscopy keywords. The obtained results were screened for the Title and abstract by to authors and the relevant papers were reviewed for further details. Sensitivity, specificity and accuracy of MRS were 74.03%, 74.27% and 77.26%, respectively, in differentiating benign and malignant prostate lesions. The increase of choline and myoinozytol, reduction of citrate and polyamine, and the ratio of the higher sum of choline and creatine to citrate in malignant lesions are presented as the main markers. MRS as a non-invasive method has an optimal sensitivity, specificity and accuracy compared with other clinical and pathological methods.